in

Topical JAK Inhibitor Shows Improvement for PN

Source link : https://newshealth.biz/health-news/topical-jak-inhibitor-shows-improvement-for-pn/

ORLANDO, Fla. — The topical Janus tyrosine kinase (JAK) 1/2 inhibitor ruxolitinib improved itching and nodules in patients with prurigo nodularis (PN) significantly better than a vehicle within a week after starting therapy, with improvements continuing out to 3 months, in a global phase 3 clinical trial. Shawn Kwatra, MD “There’s statistical significance at week […]
The post Topical JAK Inhibitor Shows Improvement for PN first appeared on News Health.

Author : News Health

Publish date : 2025-03-17 07:37:00

Copyright for syndicated content belongs to the linked Source.

Chargé d’Affaires John McNamara – USEmbassy.gov

Unique: Mikel Arteta able to set off €58 million launch of long run Arsenal goal